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Objective: To evaluate the upgrade rate and delayed false-negative results of percutaneous vacuum-assisted removal (VAR) 
and surgical excision in women with imaging-histologic discordance during ultrasound (US)-guided automated core needle 
biopsy (CNB) of the breast and to validate the role of VAR as a rebiopsy method for these discordant lesions.
Materials and Methods: Percutaneous US-guided 14-gauge CNB was performed on 7470 patients between August 2005 and 
December 2010. Our study population included 161 lesions in 152 patients who underwent subsequent rebiopsy due to 
imaging-histologic discordance. Rebiopsy was performed using VAR (n = 88) or surgical excision (n = 73). We investigated 
the upgrade rate immediately after rebiopsy and delayed false-negative results during at least 24 months of follow-up after 
rebiopsy. We also evaluated the clinicoradiological differences between VAR and surgical excision.
Results: Total upgrade to malignancy occurred in 13.7% (22/161) of lesions at rebiopsy including both VAR and surgical 
excision: 4.6% (4/88) of VAR cases (4/88) and 24.7% (18/73) of surgical excision cases (p < 0.001). Surgical excision was 
performed significantly more frequently in older patients and for larger-sized lesions than that of VAR, and a significant 
difference was detected between VAR and surgical excision in the Breast Imaging and Reporting and Data System category 
(p < 0.007). No delayed false-negative results were observed after VAR or surgical excision during the follow-up period.
Conclusion: Long-term follow-up data showed no delayed cancer diagnoses after US-guided VAR in imaging-histologic 
discordant lesions of the breast, suggesting that VAR might be a rebiopsy method for these lesions.
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INTRODUCTION
Ultrasound (US)-guided core needle biopsy (CNB) is an 
accurate and standard method for sampling lesions that 
are visible on US (1). However, CNB may underestimate 
results (2, 3) or produce false-negative results (4, 5), and 
various factors can affect CNB accuracy (6). Therefore, many 
solutions have been suggested, including confirmation of 
lesion retrieval by specimen radiography, correlating post-
biopsy imaging and histology, larger sampling for imaging-
histologic discordant lesions, and follow-up after benign 
biopsy results (7). 
The frequency of imaging-histologic discordance has been 
reported to be 1–6%, and several studies have reported 
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imaging-histologic discordance following stereotactic CNB 
(4, 8, 9) and US-guided CNB (1, 6, 8, 10-12). These reports 
show malignancy rates of 6.8–29.3% in imaging-histologic 
discordant lesions during US-guided biopsy (1, 6, 10, 12-
15), suggesting that rebiopsy of those lesions will yield 
benign pathology in approximately 70.7–93.2% of cases. 
Considering the large percentage of benign pathology at 
rebiopsy, Kim et al. (12) used vacuum-assisted removal (VAR) 
on discordant cases for a definitive diagnosis. However, 
the number of patients in that study was small (n = 26), 
and the follow-up period was limited. Some investigators 
have reported results of VAR management of imaging-
histologic discordant lesions (13, 15). However, the number 
of patients in those studies was small (n = 28 and 55), 
and they used a 16-gauge core biopsy needle instead of 
a 14-gauge core biopsy needle (13, 15). Moreover, their 
follow-up period was 12 months, which is insufficient to 
confirm the absence of false-negative biopsy results after 
VAR.
Therefore, the purpose of this study was to evaluate 
the upgrade rate and delayed false-negative results of 
percutaneous VAR in women with imaging-histologic 
discordance during US-guided automated CNB of the 
breast and to compare these results with those of surgical 
excision.
MATERIALS AND METHODS
This retrospective study was approved by our Institutional 
Review Board, and informed consent was waived.
Patients and Biopsy Technique
Percutaneous US-guided 14-gauge CNB was performed on 
7470 female patients between August 2005 and December 
2010. US-guided CNB was performed using a free-hand 
technique, guided by a 5–10 MHz or 5–12 MHz linear-
array transducer (ATL HDI 5000 or iU-22 Philips Advanced 
Technology Laboratories, Bothell, WA, USA). A 14-gauge 
semi-automated CNB (Stericut, TSK Laboratory, Tochigi, 
Japan) was used. All biopsies were performed by one of six 
full-time board-certified radiologists dedicated to breast 
imaging. The radiologists had varying degrees of experience 
in breast imaging of 1–10 years. Typically, four or five core 
samples were obtained, and the number of core samples 
was determined at the discretion of each radiologist. 
Imaging-Histologic Correlation and Post-Biopsy 
Management
All breast-dedicated radiologists reviewed the final 
pathological reports for all biopsied lesions on a weekly 
basis. These reports were reviewed in conjunction with 
mammographic and sonographic images within 1 week 
of biopsy. Radiologists determined whether the imaging 
findings and histological results were concordant or 
discordant. The imaging and histological findings were 
considered “concordant” when the histological findings 
provided an acceptable explanation for the imaging features 
and “discordant” when they did not (12). Discordant lesions 
included: 1) lesions that were suspicious for malignancy, 
e.g., Breast Imaging and Reporting and Data System (BI-
RADS) category 4 (16), when the histological findings did 
not account for the imaging features (12); and 2) lesions 
that were highly suggestive of malignancy, e.g., BI-RADS 
category 5, revealing benign histological results, unless 
the specific histology accounted for the imaging features. 
Findings were considered “concordant” after a consensus 
was obtained among all the radiologists on each case. 
However, if at least one radiologist disagreed, the lesion 
was regarded as “discordant”. 
Vacuum-assisted removal (Mammotome; Ethicon 
Endo Surgery, Cincinnati, OH, USA) was recommended 
for discordant lesions (12). VAR was performed after 
administering local anesthesia. The gauge of the probe used 
was determined by the lesion size: an 8-gauge probe for 
lesions > 1.5 cm, an 11-gauge probe for lesions < 1.0 cm, 
and an 8-gauge or 11-gauge probe for lesions 1.0–1.5 cm 
in the largest dimension, according to the patient’s breast 
thickness after a small skin incision. Multiple core samples 
were obtained under US guidance until the mass was 
completely removed. Skin tears or chest wall muscle injuries 
were regarded as serious complications (12). A US image 
was taken after biopsy to verify that the mass had been 
removed completely. 
Some lesions were surgically excised, and this decision 
was made at the discretion or request of the physician or 
patient. Thus, 265 lesions in 250 patients were assessed 
as imaging-histologic discordant results after the imaging-
histologic correlation was performed. Among all lesions, 
we excluded 66 lesions that had undergone imaging follow-
up without rebiopsy, such as VAR or surgical excision, at 
our institution. We also excluded 38 lesions in which the 
histological findings mandated a surgical excision regardless 
of the US findings, including papilloma (n = 13), atypical 
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ductal hyperplasia (n = 3), phyllodes tumor (n = 1), and 
discordant malignant lesions (n = 21). Therefore, our study 
population included 152 patients with 161 lesions (Fig. 1). 
Of the patients who underwent VAR and surgical excision, 
97 (64%, 97/152) were followed for more than 24 months 
(median, 43 months; range, 24–88 months). Patients with 
less than 24 months of follow-up after VAR (n = 36) or 
surgical excision (n = 19) were contacted by phone to ask 
about breast cancer occurrence thereafter. 
Data Analysis
The lesions were classified into the final US BI-RADS 
assessment categories prior to US-guided CNB (16). Surgical 
excision or follow-up US, imaging studies, and histological 
findings were reviewed, and follow-up data were obtained 
for breast lesions with imaging-histologic discordance at 
the initial percutaneous 14-gauge CNB and that underwent 
subsequent VAR. 
Age, BI-RADS category, and histological results were 
reviewed from medical records. We calculated the discordant 
lesion upgrade rates for VAR and surgical excision. Upgrade 
was defined when a patient had at least one lesion 
classified as a carcinoma at VAR or surgical excision. The 
upgrade rate was assigned to patients with ductal carcinoma 
in situ or invasive carcinoma. We also investigated delayed 
false-negative results during the follow-up period after VAR 
or surgical excision. Statistical analyses were performed 
using the chi-square test for categorical variables and the t 
test for continuous variables. The data were processed with 
the SPSS ver. 20.0 statistical software package (SPSS Inc., 
Chicago, IL, USA). 
RESULTS
Differences in Clinical and Radiological Findings 
between VAR and Surgical Excision
Among the 161 lesions in 152 patients who had 
discordant results after the imaging-histologic correlation, 
73 lesions were removed by surgical excision and 88 lesions 
were removed by VAR. All 152 patients were female with 
a median age of 45 years (range, 19–77 years; mean, 
45.4 years). Among the 88 breast lesions with VAR, 62 
were biopsied with an 8-gauge probe, and 26 lesions were 
biopsied with an 11-gauge probe. The median number of 
acquired tissue samples was 17 (range, 6–176). No serious 
complications were observed after VAR. 
Older patients were referred to surgical excision (mean ± 
standard deviation [SD], 47.9 ± 10.1 years) more often than 
VAR (mean ± SD, 43.2 ± 10.9 years) (p = 0.007) (Table 1). 
Additionally, the lesions that were surgically excised were 
larger than the lesions that received VAR (16.9 ± 10.8 mm 
vs. 13.6 ± 6.3 mm) (p = 0.021). A significant difference 
was observed in the BI-RADS category for VAR and surgical 
excision (p = 0.026); surgical excision was performed more 
often for lesions in categories 4c and 5 compared to VAR. 
Histological Results after CNB and Subsequent VAR and 
Upgrade Rates
Table 2 shows the initial histological results that included 
Table 1. Age, Lesion size, BI-RADS Categories According to 
Tissue Acquisition Method in Imaging-Histologic Discordant 





Patient age (mean ± SD)  43.2 ± 10.9 47.9 ± 10.1
Lesion size (mm)
  (mean ± SD)
13.6 ± 6.3 16.9 ± 10.8
BI-RADS category
4a 41 (46.6) 24 (32.9)  
4b 32 (36.4) 24 (32.9)
4c 14 (15.9) 18 (24.6)
5 1 (1.1)  7 (9.6) 
Note.— Numbers in parenthesis are percentages. BI-RADS = Breast 
Imaging and Reporting and Data System, SD = standard deviation, 
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imaging-histologic discordant lesions (n = 161). Twenty-
two lesions (VAR 4.6%, 4/88; surgical excision 24.7%, 
18/73) were upgraded to malignant after rebiopsy (Figs. 
2, 3). A significant difference in the upgrade rate was 
observed between VAR and surgical excision (p < 0.001). 
The histological profiles of initial CNB, VAR, and surgical 
excision in the upgraded lesions (n = 22) are listed in Table 
3.
Delayed False-Negative Results after VAR
No delayed false-negative results (i.e., no delayed cancer 
diagnosis) were observed in the follow-up patients after 
VAR or surgical excision (VAR; 0%, 0/83; and surgical 
excision; 0%, 0/69).
DISCUSSION
Ultrasound-guided CNB is an easily accessible and 
accurate method to diagnose breast lesions. However, 
underestimated rates and false-negative results could be a 
drawback of US-CNB as a biopsy method (2-5). Therefore, 
the imaging-histologic correlation after US-CNB is widely 
used as a method to reduce the false-negative and 
underestimated results of CNB. Additionally, larger samples 
are required for imaging-histologic discordant lesions, so 
surgical excision has traditionally been used to biopsy 
such lesions (10). However, VAR was recently reported as 
an alternative to surgery because of its efficacy (12, 13, 
15, 17, 18). Rajan et al. (18) reported adopting vacuum-
assisted biopsy (VAB) instead of diagnostic surgery for 
lesions of uncertain malignant potential, such as radial 
scars, papillomas, flat epithelial atypia, atypical ducal 
hyperplasia, and atypical lobular hyperplasia, to reduce the 
number of benign-diagnosed surgical biopsies, suggesting 
VAB as an alternative biopsy method to surgery. We focused 
only on the VAR indication in cases of imaging-histologic 
discordance after 14-gauge CNB but we did not include high 
risk lesions, as in Rajan et al. (18). Many studies (1, 6, 9, 
10, 12, 13, 15, 19) have reported the role of VAR; however, 
they included all VAR cases, not just those that were 
imaging-histologic discordant. Son et al. (1) performed 
VAR in 53 lesions among 103 imaging-histologic discordant 
cases, but we included a larger study population with 
Table 2. Initial Histologic Results of Imaging-Histologic 
Discordant Lesions (n = 161)










Note.— *Fibrous tissue (n = 2), organizing thrombus (n = 1), 
columnar cell change (n = 1). CNB = core needle biopsy
A B C
Fig. 2. 51-year-old woman with mammographic abnormality.
A. Left mediolateral oblique mammography view shows partially obscured hyperdense mass. B. Transverse sonogram corresponding to 
mammographic abnormality shows microlobulated hypoechoic mass (arrows) classified as Breast Imaging and Reporting and Data System category 
4a. Ultrasound-guided core needle biopsy reveals fibrocystic change; however, this result was regarded as discordant benign. C. Eleven-gauge 
vacuum-assisted removal (arrowheads) was performed, and histological results indicated invasive ductal carcinoma. 
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discordant results (1). 
We evaluated the difference in upgrade rates between 
VAR and surgical excision and the role of VAR as a rebiopsy 
method for imaging-histologic discordant lesions after 
US-guided CNB with long-term follow-up results. The 
upgrade rate in the imaging-histologic discordant lesions 
after VAR or surgical excision has been reported to be 
6.8–29.3% (Table 4) (1, 6, 10, 12-15). The upgrade rates 
in our study were 4.6% and 24.6% for VAR and surgical 
excision, respectively, which is similar to the range reported 
previously. Surgical excision was performed significantly 
more frequently on older patients, with larger lesions, 
and on category 4c and 5 lesions compared to those of 
VAR. These results suggest that the rebiopsy method 
was determined by the surgeon’s discretion with patient 
preference limited in scope. The most significant reason 
for the differences between VAR and surgical excision was 
that surgeons directly performed therapeutic surgery after 
confirming the frozen excisional biopsy result for more 
suspicious lesions rather than VAR. Our upgrade rate was 
13.6% in all lesions; however, if all lesions were surgically 
excised, unnecessary surgery could reach up to 86.4%. 
Therefore, VAR could be an alternative method for reducing 
needless surgery and planning a well-designed operation. 
Kim et al. (12) also reported that surgical excision was 
performed more frequently on BI-RADS category 4c lesions 
compared to VAR, compatible with our result. However, 
that study reported no difference between VAR and surgical 
excision, unlike our study (12). 
Liberman et al. (10) reported that 10.5% (2/19) of 
their results were immediate false negatives under US-
guidance during a 7-year period. Their upgrade rate to 
malignancy (10.5%) was higher than our upgrade rate 
(4.6%), though these two results are almost within the 
previously reported range (6.8–29.3%) (1, 6, 10, 12-15). 
Imaging-histologic discordance tends to be determined by 
the radiologist’s experience rather than by well-established 
criteria. However, the upgrade rates of these discordant 
lesions were still greater than the reported 2% probability 
of malignancy in BI-RADS category 3, which are primarily 
benign lesions. Thus, larger tissue samples are required for 
A B C
Fig. 3. 77-year-old woman with palpable mass in her left breast.
A. Left mediolateral oblique mammography view shows irregular shaped hyperdense mass. B, C. Transverse (B) and longitudinal (C) sonogram 
corresponding to palpable site shows irregular and hypoechoic mass (arrows) classified as Breast Imaging and Reporting and Data System 
category 5. Ultrasound-guided core needle biopsy revealed intraductal papilloma; however, this result was regarded as discordant benign. Surgical 
excision was performed, and histological results revealed ductal carcinoma in situ.
Table 3. Frequency of Carcinoma after VAR or Surgical Excision 
in Imaging-Histologic Discordant Lesions (n = 22)
CNB Results VAR (n = 4)
Surgical Excision 
(n = 18)
Fibroadenoma 0 DCIS (1)




Adenosis 0 DCIS (1)
Stromal fibrosis DCIS (1) DCIS (1)
Ductal epithelial  
  hyperplasia
IDC (2) IDC (3)
Duct ectasia 0 IDC (1)
Other* 0 IDC (1), ILC (1)
Note.— *Fibrous tissue, organizing thrombus. CNB = core needle 
biopsy, DCIS = ductal carcinoma in situ, IDC = invasive ductal 
carcinoma, ILC = invasive lobular carcinoma, VAR = vacuum-
assisted removal
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imaging-histologic discordant lesions. Appropriate follow-up 
should be performed after benign biopsy results to prevent 
immediate and delayed false-negative results. 
No delayed cancer diagnoses were made in either the 
follow-up patients or patients contacted by phone in the 
present study. A few studies have reported delayed false- 
negative results (20-23), Peter et al. (21) reported a 1.4% 
rate of delayed false-negative results; however, their results 
were obtained by stereotactically guided vacuum biopsy, 
instead of US-guided VAR; thus, they could not warrant 
complete removal of the lesions. Unlike US-guidance, it is 
difficult to completely remove lesions with stereotactic VAB 
because lesion boundaries cannot be assessed during the 
procedure, which may explain their delayed false-negative 
results. Perez-Fuentes et al. (20) reported no delayed false-
negative results after US-guided 11-gauge VAB. Although 
their complete removal rate was limited to 88.6% (78/88 
lesions) and 24-month follow-up data were available for 71 
lesions, their study was not confined to imaging-histologic 
discordant lesions. Two other studies (22, 23) reported no 
delayed false-negative results after VAR for benign lesions. 
However, their indication was benign lesions; thus, delayed 
false-negative results were not within the scope of those 
studies. Therefore, the current study is the first to report 
a lack of VAR delayed false-negative results in imaging-
histologic discordant lesions with a large number of 
patients and a long-term follow-up.
Our study had several limitations. First, the VAR and 
surgery groups were not randomized due to the retrospective 
nature of the study and were dissimilar in major patient 
characteristics, as the rebiopsy method was determined 
according to the surgeon’s discretion. The most significant 
reason for the differences between VAR and surgical 
excision was that the surgeon directly performed the 
therapeutic surgery after confirming the frozen excisional 
biopsy result for more suspicious lesions rather than VAR. 
Although our results suggest applying VAR more broadly, 
a prospective randomized study will be necessary to solve 
this limitation. Second, some patients who did not have 
sufficient imaging follow-up data, including those with 
less than a 24 month follow-up, were contacted by phone 
regarding the occurrence of breast cancer after VAR (n = 
36) or surgical excision (n = 19). These patient’s responses 
were not verified by imaging follow-up; however, the phone 
interviews were performed more than 2 years after VAR or 
surgical excision. Therefore, no cancer occurrence after more 
than 2 years was evident. 
In conclusion, long-term follow-up data showed no 
delayed cancer diagnoses after US-guided VAR in imaging-
histologic discordant lesions of the breast; thus, VAR might 
be considered a rebiopsy method for imaging-histologic 
discordant lesions. 
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